Product datasheet

anti-AAV9, human chimeric, ADK9-h1

Short overview

Cat. No.	692378
Quantity	1 ml
Concentration	50 µg/ml

Product description

Host	Recombinant chimeric (human Fc region)
Antibody Type	Monoclonal
Isotype	IgG1
Conjugate	Unconjugated
Purification	Affinity chromatography
Storage	2-8°C
Intended use	Research use only
Application	Dot blot, Neutralization assay, Serology ELISA
Reactivity	AAV9
No reactivity	AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV8, AAVDJ, AAVrh10, AAVrh74

Applications

Serology Assay	0.1-0.4 µg/ml (1:125-1:500; AAV9 ELISA)
Dot Blot	0.1 µg/ml (1:500; non-denaturing conditions)
Neutralization Assay	EC50 ~8 ng/ml (AAV9) - assay dependent

Background

Our human chimeric AAV antibodies are derived from our mouse monoclonal AAV antibodies and are a combination of the mouse antigen binding region and a human Fc region. Therefore, it provides the well-known characteristics of the corresponding mouse monoclonal antibody (anti-AAV9, ADK9, Cat. No. 690162) like cross-reactivity and neutralization activity combined with a human Fc region allowing the use in an anti-human secondary antibody detection system.

Many humans in the general population have developed antibodies against AAV as a result of naturally acquired infections, which might affect efficacy and safety of the gene transfer using AAV vectors. Therefore, testing for pre-existing AAV antibodies in patient sera is an indispensable step for the selection of patients for AAV gene therapy clinical trials.

Our human chimeric AAV antibodies are close to the human derived samples, making them the ideal positive control for reproducible and comparable serological assays.

Product images



anti-AAV9, human chimeric, ADK9-h1



Dot blot analysis of AAV9 native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids with mouse monoclonal AAV9 antibody clone ADK9 and human chimeric AAV9 antibody clone ADK9-h1. The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV9 (intact particle) mouse monoclonal, ADK9 (Cat. No. 690162) or anti-AAV9, human chimeric, ADK9-h1 (Cat. No. 692378) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-mouse IgA goat polyclonal, HRP conjugate or anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1.5 h at RT. The bands were visualized by chemiluminescent detection using Pierce ECL Western Blotting Substrate.

Dot blot analysis of AAV1-AAV9, AAVrh10, AAVrh74, AAVDJ native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids. The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV9, human chimeric, ADK9-h1 (Cat. No. 692378) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce ECL Western Blotting Substrate.